Search

Your search keyword '"Kirsten L. Kuiper"' showing total 2 results
Start Over Author "Kirsten L. Kuiper"
2 results on '"Kirsten L. Kuiper"'

1. Inflammatory Blood Biomarkers Are Associated with Long-Term Clinical Disease Severity in Parkinson’s Disease

Author

Dagmar H. Hepp, Thecla A. van Wageningen, Kirsten L. Kuiper, Karin D. van Dijk, Linda P. Oosterveld, Henk W. Berendse, and Wilma D. J. van de Berg

Subjects
immune response, blood biomarkers, Parkinson’s disease, disease severity, CCL23, TGF-alpha, Biology (General), QH301-705.5, Chemistry, QD1-999
Abstract

An altered immune response has been identified as a pathophysiological factor in Parkinson’s disease (PD). We aimed to identify blood immunity-associated proteins that discriminate PD from controls and that are associated with long-term disease severity in PD patients. Immune response-derived proteins in blood plasma were measured using Proximity Extension Technology by OLINK in a cohort of PD patients (N = 66) and age-matched healthy controls (N = 52). In a selection of 30 PD patients, we evaluated changes in protein levels 7–10 years after the baseline and assessed correlations with motor and cognitive assessments. Data from the Parkinson’s Disease Biomarkers Program (PDBP) cohort and the Parkinson’s Progression Markers Initiative (PPMI) cohort were used for independent validation. PD patients showed an altered immune response compared to controls based on a panel of four proteins (IL-12B, OPG, CXCL11, and CSF-1). The expression levels of five inflammation-associated proteins (CCL23, CCL25, TNFRSF9, TGF-alpha, and VEGFA) increased over time in PD and were partially associated with more severe motor and cognitive symptoms at follow-up. Increased CCL23 levels were associated with cognitive decline and the APOE4 genotype. Our findings provide further evidence for an altered immune response in PD that is associated with disease severity in PD over a long period of time.

Published
2023
Full Text
View/download PDF

2. The multifaceted therapeutic value of targeting ATP-citrate lyase in atherosclerosis

Author

Sanne G.S. Verberk, Mario A. Lauterbach, Eicke Latz, Jan Van den Bossche, and Kirsten L. Kuiper

Subjects
Drug, bempedoic acid, ATP citrate lyase, media_common.quotation_subject, immunometabolism, Systemic inflammation, chemistry.chemical_compound, Adenosine Triphosphate, Multienzyme Complexes, Medicine, Humans, Molecular Biology, media_common, business.industry, Cholesterol, Oxo-Acid-Lyases, Cholesterol, LDL, Lyase, Atherosclerosis, macrophages, ATP-citrate lyase, chemistry, Metabolic enzymes, Cancer research, ATP Citrate (pro-S)-Lyase, Molecular Medicine, medicine.symptom, business, Bempedoic acid
Abstract

ATP-citrate lyase (Acly) is the target of the new class low-density lipoprotein-cholesterol (LDL-C)-lowering drug bempedoic acid (BA). Acly is a key metabolic enzyme synthesizing acetyl-CoA as the building block of cholesterol and fatty acids. Treatment with BA lowers circulating lipid levels and reduces systemic inflammation, suggesting a dual benefit of this drug for atherosclerosis therapy. Recent studies have shown that targeting Acly in macrophages can attenuate inflammatory responses and decrease atherosclerotic plaque vulnerability. Therefore, it could be beneficial to extend the application of Acly inhibition from solely lipid-lowering by liver-specific inhibition to also targeting macrophages in atherosclerosis. Here, we outline the possibilities of targeting Acly and describe the future needs to translate these findings to the clinic.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results